Angiotech still at neutral by Merrill

Merrill Lynch analyst Hari Sambasivam kept Angiotech Pharmaceuticals Inc. unchanged at a neutral rating. Angiotech released positive two-year data from the European study of its paclitaxel eluting Vascular Wrap in femoropopliteal bypass surgery. The study met its primary endpoint of safety and showed favorable results in a number of secondary endpoints, according to the analyst. Shares of the Vancouver, B.C.-based medical technology company were up 23 cents, or 2.70%, at $8.73. (Nasdaq: ANPI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.